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1. Introduction 
Cytochrome P450 epoxygenases metabolize arachidonic acid to epoxyeicosatrienoic acids 
(EETs). One human cytochrome P450 enzyme, CYP2J2, is abundantly expressed in coronary 
artery endothelial and smooth muscle cells, and in cardiac myocytes (Wu et al., 1996; Imig, 
2000). One of the primary products of the NADPH-dependent epoxidation of arachidonic 
acid by CYP2J2 is the production of 11, 12-EET. This eicosanoid has potential anti-
inflammatory effects by inhibiting endothelial nuclear factor- B, a transcription factor 
associated with the induction of many pro-inflammatory gene products in the vasculature 
(Imig, 2000; Node et al., 1999). Other EETs, including 5,6-, 8,9-, 11,12-, and 14,15-EETs have 
important vasodilatation properties via mechanism of smooth muscle cells relaxation (Fang 
et al., 2002; Pinto et al., 1987; Spieker & Liao, 2005; Liu et al., 2006). More recently, the 
additional vascular protective effects of EETs, including anti-thrombotic, antimigratory, 
antioxidant, and antiapoptotic effects, have also been observed (Gauthier et al., 2004; Sun et 
al., 2002). 
Recently, a novel genetic variant G-50T of this novel gene CYP2J2 was found to be 
associated with coronary artery disease (CAD) (Spieker et al., 2004). This mutation could 
functionally result in the loss of binding of the Sp1 transcription factor to the CYP2J2 
promoter and a decreased activity in CYP2J2 promoter. The plasma concentrations of stable 
EETs metabolites were also lower in individuals with the G-50T polymorphism. However, 
the role of this novel gene variant in myocardial infarction (MI), especially premature MI, is 
still not well investigated. 
Of the common environmental factors known to be associated with risk of acute MI, 
smoking is widely acknowledged to make a major contribution (Manson et al., 1992; Teng et 
al., 1994). Smoking can disturb lipoprotein metabolism by increasing insulin resistance and 
lipid intolerance, and is implicated in the production of small dense low-density lipoprotein 
(Craig et al., 1989; Eliasson et al., 1997; Barua et al., 2002). The smoking-associated risk of MI 
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has been reported to be greater in subgrouping subjects with several genetic variants 
background (Li et al., 2002; Liu et al., 2005; Humphries et al., 2002). 
We thus hypothesized that those who with the T allele may have higher inflammatory 
status, and thus have higher risk for plaque rupture or occurrence of MI, especially at a 
younger age. We also speculated that there should be an additive interaction between the 
effect of smoking behavior and the genetic variation for the onset of premature MI. 
Smoking cessation could gradually improve the endothelial function and fibrinolytic status 
(Tsiara et al., 2003). However, successful cessation of smoking after MI and its interaction 
with this candidate gene for the subsequent events after index MI was still undefined. Thus, 
we hypothesized that premature MI patients carrying genetic polymorphism, especially 
genetic variant G-50T of this novel gene CYP2J2, might have a higher risk for subsequent 
coronary events. In addition, smoking cessation might interact with these gene variations for 
the prognosis after patients’ index MI in Taiwan. 
2. Methods 
2.1 Study subjects 
2.1.1 Study population  
We enrolled 200 patients (mean age 42.2±2.5 years; 84% men) with documented MI onset 
prior to age of 45 years. The patients were recruited after their first MI. Diagnosis of MI was 
based on ischemic chest symptoms, typical electrocardiographic changes and elevation of 
serum creatine kinase and its MB isoenzyme, when more than twice the upper level of 
normal. Coronary angiography was performed using the Judkin’s method within 2 weeks 
after the onset of symptoms. Coronary stenosis is defined as  50% diameter narrowing.  
2.1.2 Control population  
The control group was recruited by sex-matched 200 patients (mean age 42.5±2.1 years) 
from consecutive subjects admitted to our hospital for routine health examinations. They 
did not show any clinical or electrocardiographic evidence of MI or CAD. They also had no 
history of cerebrovascular disease or peripheral arterial disease. Written informed consents 
were obtained from all patients and this study was in agreement with guidelines approved 
by the research committee of National Cheng-Kung University Hospital.  
2.1.3 Background of population  
All patients and controls included in this study are Han Chinese/Taiwanese from the same 
geographic area. The demographic data and the presence of traditional coronary risk factors, 
including hypertension, diabetes mellitus, smoking and serum cholesterol, were collected 
from all study participants.  
2.1.4 Data collection & history recording  
For patients with MI, these data were taken from the medical records at the time of 
admission for acute MI; for control subjects, they were collected at the time of hospital 
admission for routine health examinations. They were considered to have hypertension if 
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elevated blood pressure (>140/90 mmHg) were measured on 3 occasions or if they were 
already being treated with anti-hypertensive agents. They were defined as having diabetes 
mellitus (DM) if they had a fasting blood glucose level > 110 mg/dl or were already being 
treated for DM. All study participants were classified as either smokers (including current 
or ex-smokers) or non-smokers. The total cholesterol level was determined at the beginning 
of the study. 
2.1.5 Blood collection  
The blood sampling time in the study group was at least 2 weeks after the onset of acute MI. 
In the control group, the blood samples were taken during coronary angiography study. All 
patients with impaired renal function, malignancy, connective tissue disease or chronic 
inflammatory disease were excluded. The blood samples were drawn into a 5-ml EDTA 
glass tube and centrifuged at 2200 g for 15 minutes to separate the plasma contents. The 
buffy coat after centrifugation was obtained and deoxyribonucleic acid (DNA) in each 
sample was isolated by the method we used before (Liu et al., 2007). The DNA samples were 
stored at –70 degree C until use. 
2.1.6 Genomic amplification by PCR  
Patient’s DNA was isolated from the whole-blood samples by the phenol-chloroform 
extraction method. A 273-bp promoter region proximal to the transcriptional start site was 
amplified with primers described previously (King et al., 2002). The sequence products were 
resolved on an ABI 377 automated sequencer. The promoter polymorphism G-50T was 
verified by direct sequencing. The numbering of the polymorphisms refers to the GenBank 
sequence AF272142 (accession number). 
2.1.7 Functional EET analysis  
Eicosanoids were extracted from plasma samples 3 times with ethyl acetate after acidification 
with acetic acid. After evaporation, saponification with 0.4N KOH in methanol, and re-
extraction, concentrations of the stable EETs metabolite 14,15-dihydroxyeicosatrienoic acid 
(DHET) were determined by an ELISA kit (Detroit R&D) (Liu et al., 2007; Spieker et al., 2004). 
2.1.8 Smoking habits definition  
Individuals were classified according to their smoking status; a current smoker was defined 
as any person who smoked regularly (at least one cigarette per day and/or one cigar or one 
pipe per week). Subjects who had smoked at least one cigarette per day and/or one cigar or 
one pipe per week in the past were classified as former smokers. Never smokers were those 
who had never smoked any tobacco product regularly. Subjects were considered to have 
achieved smoking cessation if they were reported non-smoking from the quitting day until 
the end of the 6-month period. 
2.1.9 Follow-up study  
Patients received regular follow-up care in our cardiology ward or clinics for at least 6 
months with a maximum of 13 years or until occurrence of one of the following coronary 
events: recurrent angina pectoris, non-fatal MI, or cardiac death. Recurrent angina pectoris 
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was defined as recurrent chest pain with ischemic ECG changes lasting >10 min despite 
antiangina therapy. Diagnosis of recurrent MI was the same as for index MI (see Study 
population). Cause of death was determined from hospital records. In this study, the follow-
up data were available for a total of 162 (95.3%) premature MI patients. Eight patients (4.7%) 
were not available for follow-up. The reasons included: 3 (1.8%) patients moved back to 
their primary residency region and we were unable to follow-up; 3 (1.8%) patients died of 
non-cardiovascular events, including two (1.2%) in traffic accidents and one (0.6%) by 
suicide; two (1.2%) patients were lost or changed their telephone numbers without detailed 
medical records. Those event-free patients who we were unable to follow-up completely 
were included in the event-free group. Their follow-up periods were defined between the 
index MI and their last clinic visit. 
2.1.10 Statistical analysis  
Data on age and cholesterol levels were presented as mean value ± standard deviation (SD). 
The values of DHET were presented as median ± SD. The difference between the groups was 
analyzed by the unpaired Student’s t test. The differences in the frequencies of smoking, 
hypertension, hyperlipidemia, diabetes mellitus, and CYP2J2 G-50T genotypes were analyzed 
by Fisher’s exact test. 2 analyses were used to test deviations of genotype distribution from 
Hardy-Weinberg equilibrium and to determine allele or genotype frequencies between 
patients and control groups. The risk factors that appear to be possible significant predictors 
(p<0.05) in the single-variant analyses were included in the multiple logistic regression 
analyses. Multivariate analyses were conducted with multiple logistic regression methods, and 
adjusted estimations of conditioned relative risk and 95% confidence intervals (CIs) were done. 
The Kaplan–Meier method (log-rank test) was applied in subsequent event-free analysis. All 
statistical analyses were performed using SPSS Advanced Statistics 13.0 for Window. In this 
study, a value of p<0.05 was taken to be statistical significance. 
3. Results 
3.1 Comparison of traditional CAD risk factors between MI and control groups 
We compared the control and premature MI group for traditional CAD risk factors, 
including hypertension, diabetes mellitus, smoking and serum cholesterol levels (Table 1).  
 
Characteristics Control (n=200) Premature MI (n=200) 
Age (yrs) 42.5±2.1 42.2±2.1 
Men/Women 167/33 168/32 
Systemic hypertension (%) 46 (23.0) 60 (30.0) † 
Diabetes mellitus (%) 9 (4.5) 26 (13.0)* 
Smoker (%) 89 (44.5) 154 (77.0)* 
Total cholesterol (mg/dL) 182±37.5 210±34.5 
Triglycerides (mg/dL) 135±32.1 136±30.8 
HDL cholesterol (mg/dL) 46±10.5 41±10.1 
LDL cholesterol (mg/dL) 120±29.3 128±21.5 
Data are presented as number (%) of patients or mean ± standard deviation. HDL = high-density 
lipoprotein; LDL = low-density lipoprotein; MI = myocardial infarction. *: p<0.001; †: p<0.01.  
Table 1. Clinical characteristics of study subjects  
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There were no significant differences in the age between these 2 groups (p = 0.890). The 
frequency of smoking (p <0.001), diabetes mellitus (p <0.001) and hypertension (p <0.01) 
were significantly higher in premature MI patients. However, the traditional CAD risk 
factor such as total cholesterol level was similar between 2 groups. 
3.2 Distribution of CYP2J2 G-50T genotypes 
Table 2 shows the distribution of CYP2J2 G-50T genotype in both premature MI patients and 
control subjects. The frequency of the T allele was significantly higher in the premature MI 
than the control group (16.0% vs. 12.0%, p<0.01; odds ratio (OR) 2.15, 95% [CI] 1.30 to 6.80). 
There was a significantly higher prevalence of the T allele genotype (GT+TT) among 
patients with premature MI in comparison to the control subjects (28.0% vs. 22.0%; OR 2.0, 
95% [CI] 1.3 to 6.8, p = 0.01). The distributions of genotype in both the premature MI group 
and control group were compatible with the Hardy-Weinberg equilibrium. 
 Control (n=200) Premature MI (n=200) OR (95% CI) P value 
TT 4 (2.0) 8 (4.0)   
GT 40 (20.0) 48 (24.0)   
TT+GT 44 (22.0) 56 (28.0) 2.0 (1.3-6.8) 0.01 
GG 156 (78.0) 144 (72.0)   
T allele frequency 0.12 0.16  0.01 
Data are presented as number (%) of patients. CI = confidence interval; GG = homozygous G allele of 
CYP2J2 G-50T gene; GT = heterozygous allele of CYP2J2 G-50T gene; MI = myocardial infarction; TT = 
homozygous T allele of CYP2J2 G-50T gene; OR = odds ratio. 
Table 2. Frequency of genotypes of CYP2J2 G-50T gene in control subjects and patients with 
premature myocardial infarction  
3.3 Identification of independent risk factors of MI 
Table 3 shows the results of multiple logistic regression analysis for identifying the 
independent risk factors of premature MI. Hypertension, DM, smoking and CYP2J2 genotype 
were all used as independent variables. Multiple logistic regression analysis showed that the T 
allele was an independent risk factor (OR 1.78, 95% CI 1.12 to 6.40, p = 0.02), as well as 
smoking (OR 3.05, 95% CI 1.55 to 7.25, p<0.01), diabetes mellitus (OR 3.24, 95% CI 1.22 to 6.55, 
p<0.01) and hypertension (OR 1.95, 95% CI 1.13 to 5.73, p<0.01) for the premature onset of MI. 
 
 OR for MI 95% CI P value 
Smoking 3.05 1.55-7.25 <0.01 
Diabetes mellitus 3.24 1.22-6.55 <0.01 
Hypertension 1.95 1.13-5.73 <0.01 
CYP2J2 G-50T polymorphism 1.78 1.12-6.40 0.02 
CI = confidence interval; GG = homozygous G allele of CYP2J2 G-50T gene; GT = heterozygous allele of 
CYP2J2 G-50T gene; MI = myocardial infarction; TT = homozygous T allele of CYP2J2 G-50T gene; OR = 
odds ratio. 
Table 3. Risk factors of premature myocardial infarction identified by multiple logistic 
regression analysis  
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Moreover, there was a synergistic effect between smoking and T allele of CYP2J2 genotype 
on the occurrence of MI. (Table 4.) Among patients who did not smoke, the T allele was 
associated with a higher risk of young MI (OR 1.43, 95% CI 1.2 to 6.2). Smoking carrier with 
the G allele was associated with a 3-fold higher risk for premature MI (OR 3.78, 95% CI 3.3 
to 10.6). Furthermore, smoking carriers of the T allele of CYP2J2 allele had a significantly 5.6-
fold higher risk of premature MI (OR 5.55, 95% CI 4.3 to 13.7) when compared with non-
smoking and G allele genotype carriers. 
 
Smoking 
CYP2J2 G-50T 
genotype 
Control (n=200)
Premature MI 
(n=200) 
OR 95% CI 
No GG 87 36 1  
No GT+TT 24 10 1.43 1.2-6.2 
Yes GG 69 108 3.78 3.3-10.6 
Yes GT+TT 20 46 5.55 4.3-13.7 
 
Data are presented as number of patients. CI = confidence interval; GG = homozygous G allele of 
CYP2J2 G-50T gene; GT = heterozygous allele of CYP2J2 G-50T gene; MI = myocardial infarction; TT = 
homozygous T allele of CYP2J2 G-50T gene; OR = odds ratio 
Table 4. Association between smoking and CYP2J2 G-50T genotype on premature 
myocardial infarction  
3.4 Functional analysis of EET metabolites  
To further investigate the functional role of the G-50T polymorphism, we measured the 
plasma concentrations of the major CYP2J2-dependent epoxidation product from 
arachidonic acid. Given the instability of the primary products, EETs, concentration of the 
stable metabolite 14,15-DHET was determined after extraction from plasma samples. 
Median DHET plasma concentrations were significantly lower in samples from premature 
MI subjects with the G-50T polymorphism when compared with G allele individuals (6.2 ± 
1.2 ng/mL vs. 10.8 ± 2.5 ng/mL; p = 0.025). Among premature MI subjects, the median 
DHET plasma concentrations were significantly lower among smoking carriers with the G-
50T polymorphism (3.3 ± 1.0 ng/mL vs. 6.8 ± 1.3 ng/mL; p = 0.001). However, this effect 
was not significant for subjects without gene variation (G allele carriers) (10.2 ± 1.3 ng/mL 
vs. 10.8 ± 2.4 ng/mL; p = 0.18). (Fig 1) 
Median DHET plasma concentrations were significantly lower in samples from premature 
MI subjects with the G-50T polymorphism when compared with G allele individuals. 
Among premature MI subjects, the median DHET plasma concentrations were significantly 
lower among smoking carriers with the G-50T polymorphism. However, this effect was not 
significant for subjects without gene variation (G allele carriers). Median DHET levels were 
significantly lower among CYP2J2 G-50T polymorphism compared with G allele 
individuals. The median DEHT levels were significantly lower among smoking carriers with 
T allele subjects, but not among G allele ones. DHET = dihydroxyeicosatrienoic acid; MI = 
myocardial infarction. 
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Fig. 1. Plasma concentrations of the 14, 15-dihydroxyeicosatrienoic acid (DHET), a major 
CYP2J2-dependent epoxidation product from arachidonic acid among premature 
myocardial infarction subjects.  
3.5 The follow-up clinical and angiographic characteristics analyses 
During a mean period of 4.43 years (from 0.5 to 13 years) follow-up, cardiac events occurred 
in 48 (28.2%) patients, including four (2.4%) with cardiac death, 24 (14.1%) with recurrent 
MI, and 20 (11.7%) with recurrent angina pectoris. The baseline and the available follow-up 
clinical and angiographic characteristics are shown in Table 5. 
With similar mean follow-up periods, most of the clinical manifestations and treatment 
regimens were no different before and after follow-up in both groups that with-event and 
without-event, except that usage frequencies of both angiotensin-converting enzyme 
inhibitors (ACEI) and statin were higher after follow-up in both groups (P < 0.05, compared 
with their baseline data). Under these therapeutic profiles, patients’ blood pressures and 
fasting sugar levels were also similar in both groups after follow-up. Almost 92% of our 
follow-up subjects received catheterization study. The prevalence distribution of the culprit 
coronary artery lesion changed among patients receiving follow-up coronary angiography 
(Table 5).  
During the first catheterization study, most (48/84, 57.1%) patients had the culprit lesion 
located in the left anterior descending artery, followed by a right coronary artery lesion. 
However, during the late angiographic study, 31.3% of the initial culprit lesions regressed, 
while 33.8% of the new De novo lesions became culprit ones.  
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With cardiac events (n=48, 30.0%) Without cardiac events (n=114, 70.0%) 
Initial 
treatment 
Final 
treatment 
P value 
Initial 
treatment 
Final 
treatment 
P value 
Hypertension 29 (60.4) 31 (64.5) 0.14 36 (31.5) 38 (33.3) 0.15 
Diabetes 
mellitus 
19 (39.5) 21 (43.8) 0.08 20 (17.5) 28 (24.5) 0.06 
Smoking 40 (83.3) 32 (66.7) 0.04 100 (87.7) 43 (37.7) 0.01 
Total 
cholesterol, 
mg/dL 
204±33.5 208±32.7 0.24 207±36.1 207±40.7 0.36 
HDL-
cholesterol, 
mg/dL 
4210 4411 0.38 439 4412 0.33 
LDL-
cholesterol, 
mg/dL 
13532 13740 0.28 13629 13739 0.54 
Triglycerides, 
mg/dL 
13236 13756 0.42 13543 13656 0.77 
LVEF (%) 58.8±9.8 57.9±10.1 0.35 60.1±13.5 59.1±11.5 0.40 
Angiography 43 (89.9) 44 (91.6) 0.67 100 (87.7) 94 (82.4) 0.58 
PCI 25 (52.0) 29 (60.4) 0.44 60 (52.6) 59 (51.7) 0.38 
CABG 6 (12.5) 8 (16.7) 0.40 18 (15.8) 19 (16.7) 0.28 
CAD       
Single-vessel 24 (50.0) 26 (54.1) 0.32 64 (56.1) 60 (52.6) 0.85 
LAD 16 10  34 26  
LCX 3 7  9 15  
RCA 5 9  21 19  
Double-vessel 13 (27.1) 13 (27.1) 1.00 30 (26.3) 32 (28.0) 0.61 
Triple-vessel 10 (20.8) 8 (16.7) 0.44 22 (19.2) 23 (20.1) 0.22 
Medications       
β-blocker 19 (39.5) 24 (50.0) 0.06 91 (79.8) 97 (85.0) 0.10 
ACEI 10 (20.8) 20 (41.6) 0.04 69 (60.5) 80 (70.1) 0.06 
Statin 10 (20.8) 18 (37.5) 0.03 42 (36.8) 60 (52.6) 0.04 
With similar mean follow-up periods, most of the clinical manifestations and treatment regimens were 
no different before and after follow-up in both groups that with-event and without-event, except that 
usage frequencies of both angiotensin-converting enzyme inhibitors and statin were higher after follow-
up in both groups. Under these therapeutic profiles, patients’ blood pressures and fasting sugar levels 
were also similar in both groups after follow-up. Values are expressed as number (%) or mean ± SD. 
ACEI = angiotensin-converting enzyme inhibitor; CABG = coronary artery bypass graft surgery; CAD = 
coronary artery disease; CI = confidence intervals; ECG = electrocardiograms; HDL = high density 
lipoproteins; LAD = left anterior descending artery; LCX = left circumflex artery; LDL = low density 
lipoproteins; LVEF = left ventricular ejection fraction; MI = myocardial infarction; PCI = percutaneous 
coronary interventions; RCA = right coronary artery. 
Table 5. The initial and follow-up clinical and angiographic characteristics of patients with 
premature myocardial infarction  
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Compared with event-free group, subjects with event during the follow-up period had 
significantly higher genetic prevalence rate of T allele (TT+GT) (Event vs. event-free 
subjects: 58.3% vs. 42.1%, p=0.02) as well as the whole T allele frequency (Event vs. event-
free: 42.7% vs. 29.8%, p=0.02). 
CYP2J2 genotypes With event (n=48) Event-free (n=114) P value 
TT+GT 11+17 (58.3) 16+30 (42.1) 0.02 
GG 20 (41.6) 68 (60.0)  
T allele relative frequency 41/96 (42.7) 68/228 (29.8) 0.02 
Compared with event-free group, subjects with event during the follow-up period had significantly 
higher genetic prevalence rate of T allele (TT+GT) as well as the whole T allele frequency. Values are 
expressed as n (%). 
Table 6. Frequencies of CYP2J2 G-50T genotypes in groups with or without cardiac events 
after index myocardial infarction  
Kaplan–Meier analysis demonstrated a significantly lower probability (23.5% vs. 34.6%, log-
rank P=0.04) of developing clinical coronary events among patients with the polymorphism 
of CYP2J2 promoter G-50T genotype (Fig. 2). 
 
Fig. 2. Kaplan-Meier survival curve for subsequent coronary events after index acute 
myocardial infarction for the patients carrying TT or GT allele (A) (or GG allele for (B)) at 
their CYP2J2 gene (after modified risk with age, diabetes mellitus, smoking, hypertension, 
and medication usage with ACEI or β-blockers). 
For traditional risk factors, patients in event groups had significantly higher prevalence rates 
of DM, hypertension and initial severe Killip’s status (>II) (all P < 0.05, see Table 7). The mean 
cholesterol level was also higher in the event group. Compared with the event group, patients 
without events received more medications such as ACEI, β-blocker and statin. The success rate 
of smoking cessation was higher in the event-free group (52.0% vs. 19.5%). 
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However, the event-free group patients received more frequent procedures of coronary 
bypass surgery in our MI group.  
 
 
Without cardiac 
events 
(n=114, 70.0%) 
With cardiac 
events 
(n=48, 30%) 
p value 
Age (years) 40.3 ± 4.8 39.7 ± 4.4 0.43 
Sex (male) 91 (79.8) 42 (87.5) 0.50 
Family history 23 (20.1) 10 (20.8) 0.73 
Hypertension 36 (28.9) 29 (60.4) <0.01 
Diabetes mellitus 20 (17.5) 19 (39.5) <0.01 
Smoking 100 (87.7) 42 (87.5) 0.77 
Total cholesterol, mg/dL 191.4 ± 33.2 209.0 ± 35.3 <0.01 
HDL-cholesterol, mg/dL 42  11 44  9 0.22 
LDL-cholesterol, mg/dL 133  32 136  30 0.34 
Triglycerides, mg/dL 135  37 138  44 0.25 
Status of MI    
Q wave in EKG 98 (85.9) 36 (75.0) 0.47 
Peak CK level (U/L) 2845 ± 1988 2975 ± 2354 0.38 
LVEF (%) 55.4 ± 11.5 54.8 ± 12.3 0.64 
LVEF <45% 26 (22.8) 14 (29.1) 0.06 
Thrombolytic therapy 89 (78.0) 36 (75.0) 1.00 
Primary PTCA 19 (16.6) 8 (16.7) 1.00 
Coronary angiography 107 (93.8) 44 (91.6) 1.00 
PCI 61 (53.5) 25 (52.0) 0.89 
CABG 18 (15.8) 6 (12.5) 0.81 
VT/Vf at MI 9 (7.8) 4 (8.3) 0.91 
Killip’s classification  II 26 (22.8) 23 (47.9) <0.01 
Medication usage after MI    
β-blocker 91 (79.8) 19 (39.5) <0.01 
ACEI 69 (60.5) 10 (20.8) <0.01 
Statin 42 (36.8) 10 (20.8) 0.03 
Patients in event groups had significantly higher prevalence rates of DM, hypertension and initial 
severe Killip’s status (>II). The mean cholesterol level was also higher in the event group. Compared 
with the event group, patients without events received more medications such as ACEI, β-blocker and 
statin. The success rate of smoking cessation was higher in the event-free group. The event-free group 
patients received more frequent procedures of coronary bypass surgery in our MI group. Values are 
expressed as number (%) or mean ± SD. CK = creatine kinase; Vf = ventricular fibrillation; VT = 
ventricular tachycardia.  
Table 7. Comparison between patient groups with- or without- subsequent cardiac events 
during follow-up period after index myocardial infarction  
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Univariate Cox regression analyses of the clinical characteristics and genetic backgrounds of 
premature MI patients are shown in Table 8. Finally, we included the variables as DM, 
hypertension, smoking cessation after MI, multiple (>2-vessel) coronary disease, medical 
therapies with β-blockers, ACEI, or statins in traditional risk factors; and the polymorphism 
of CYP2J2 promoter G-50T genotype in genetic factors in the multiple logistic regression 
analysis. For clinical consideration, we also included factors such as treatment by 
thrombolysis or primary angioplasty or none into this survival analyses. That analysis 
showed that the polymorphism of CYP2J2 promoter G-50T genotype, DM, smoking 
cessation and use of ACEI were independent survival predictors (Table 9). 
 
 Hazard ratios (95% CI) p value 
Genetic variables 
CYP2J2 G-50T 2.78 (1.50-5.00) <0.01 
Traditional variables 
Age (>40 years-old) 1.59 (0.94-3.08) 0.07 
Sex (male) 0.66 (0.18-2.18) 0.51 
Family history vs. non-history 0.72 (0.35-1.55) 0.38 
Systemic hypertension 2.09 (1.39-5.05) <0.01 
Diabetes mellitus 2.71 (1.46-4.89) <0.01 
Smoking behavior before MI 1.89 (0.82-3.01) 0.55 
Smoking cessation after MI 0.21 (0.11-0.40) <0.01 
Total cholesterol > 200mg/dL 1.41 (0.50-1.98) 0.22 
Anterior MI vs. other wall 1.47 (0.81-1.95) 0.25 
LVEF (<45%) 0.68 (0.36-1.30) 0.25 
Thrombolytic therapy 1.42 (0.62-6.39) 0.57 
Primary PTCA 1.17 (0.93-8.78) 0.10 
Coronary angiography 0.46 (0.78-4.76) 0.88 
PCI procedure 0.53 (0.39-2.54) 0.70 
CABG 0.87 (0.72-1.32) 0.89 
VT/Vf at MI 0.77 (0.79-2.69) 0.72 
Killip’s classification  II 1.88 (1.33-6.62) <0.01 
Multiple (>2-vessel) disease 2.96 (0.84-7.25) 0.42 
Medication usage after MI   
Not-using β-blocker 2.34 (1.51-3.17) 0.01 
Not-using ACEI 7.19 (2.84-10.2) <0.01 
Not-using statin 1.65 (1.02-2.93) 0.01 
Table 8. Univariate analyses of traditional and genetic risk factors with Cox proportional 
hazards models for subsequent cardiac events. Values are expressed as number (%) or mean 
± SD.  
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 Hazard ratios (95% CI) p value 
Not-using ACEI 10.5 (2.08-14.18) <0.01 
Diabetes mellitus 2.41 (1.23-6.95) 0.01 
Smoking cessation after MI 0.33 (0.15-0.81) 0.01 
Not-using statin 1.45 (1.02-2.95) 0.04 
CYP2J2 G-50T 2.51 (1.09-5.78) 0.03 
Not-using β-blocker 1.46 (0.99-3.29) 0.06 
Multiple vessel disease 1.76 (0.88-7.56) 0.26 
Systemic hypertension 1.57 (0.84-3.57) 0.32 
Thrombolytic therapy 1.52 (0.25-8.40) 0.50 
LVEF <45% 1.34 (0.87-10.56) 0.55 
Primary PTCA 1.08 (0.80-10.12) 0.43 
Killip’s classification  II 1.48 (0.59-8.76) 0.34 
Age (>40 years-old) 1.32 (0.50-2.22) 0.65 
The variables as DM, hypertension, smoking cessation after MI, multiple (>2-vessel) coronary disease, 
medical therapies with β-blockers, ACEI, or statins in traditional risk factors; and the polymorphism of 
CYP2J2 promoter G-50T genotype in genetic factors were put in the multiple logistic regression 
analysis. That analysis showed that the polymorphism of CYP2J2 promoter G-50T genotype, DM, 
smoking cessation and use of ACEI were independent survival predictors. Values are expressed as 
number (%) or mean ± SD.  
Table 9. Multivariate analysis with Cox regression method assessing both traditional and 
genetic risk factors for subsequent cardiac events  
3.6 The modification effect and gene–environment interaction of smoking cessation  
We also analyzed the effect of smoking cessation after the smoker’s index MI. We divided 
the smoking patients into two groups, based on their successful smoking cessation or not 
after the index MI and found that successful smoking cessation could improve the outcome 
(successful smoking cessation: event vs. event-free, 25% vs. 46.3%, HR 0.26, 95% CI 0.11 to 
0.42; current smoking after index MI: event vs. event-free, 60% vs. 28.4%, HR 3.91, 95% CI 
2.37 to 8.86; P=0.003 for HR difference). Gene–environment interactions were analyzed for 
the polymorphism of CYP2J2 promoter G-50T genotype. Among the successful smoking 
cessation subjects, the risk of subsequent cardiovascular events was 1.6-fold higher among 
the G allele subgroup when compared with the T allele carrying subjects. With the same 
genetic background as T genotype, their risk was also 2.1-fold higher among current 
smokers. However, among patients who carried the G allele, the current smoking behavior 
increased the risk to 7.2-fold higher (Fig. 3). It seems that the risk could be lower after 
smoking cessation, even among high-risk gene carrying patients. 
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Fig. 3. Modification and interaction effects of the CYP2J2 G-50T gene polymorphism and the 
cessation of smoking for the risk of subsequent cardiac events 
4. Discussion 
The present study investigates the association between the polymorphism of CYP2J2 
promoter G-50T genotype and the onset of premature MI in Taiwanese population. We 
found a higher frequency of T allele in patients with premature MI than in control subjects. 
There was a significant synergistic interaction between this polymorphism and the smoking 
behavior for the onset of MI at younger age in Taiwan.  
4.1 Mechanism of the association between the polymorphism of the CYP2J2 promoter 
G-50T genotype and premature MI 
The polymorphism of CYP2J2 promoter G-50T gene has been described among different 
disease status groups, including hypertension and CAD (Spieker et al., 2004; King et al., 2005). 
Spieker et al had demonstrated a functional relevance of this genetic variant by the method of 
electrophoretic mobility shift assays in human umbilical vein endothelial cells (Spieker et al., 
2004). They found a functional consequence of reduced Sp1-DNA binding on transcriptional 
activation of the CYP2J2 gene by using transfection studies in vitro. The construction 
containing the wild type promoter induced a 2-fold higher promoter activity compared with 
the mutant G-50T construct cells. In subjects of documented CAD, the frequency of the G-50T 
polymorphism was much higher. In our study, we also demonstrate that patients with CYP2J2 
G-50T allele have higher possibility of premature MI. In addition, the T allele in the promoter 
region of CYP2J2 gene may functionally reduce EETs activities in the atherosclerotic 
vasculature, which was supported by the evidence of relationship between the genotype G-
50T and the reduced EETs activities in these MI patients. This gene-phenotype association of 
the G-50T mutation in this promoter region could be considered as one of the possible causes 
to enhance the vulnerability of the atherosclerotic plaque under stimulation.  
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4.2 The synergistic effects of the CYP2J2 G-50T genotype and smoking behavior 
In our subgroup analysis, we also demonstrate this gene-environment interaction between 
smoking behavior and the CYP2J2 G-50T polymorphism. Among non-smoker groups, the risk 
of MI in patients with T allele (CYP2J2 GT+TT) is significantly higher when compared with the 
CYP2J2 GG genotype patients (OR 1.43 and 1.0, respectively). The smoking behavior alone can 
increase 3-fold risk of MI in patients with lower activity of CYP2J2 GG genotype at the 
promoter region. However, those smokers carrying the T allele polymorphism had a 5.6-fold 
higher risk of young MI when compared with non-smoking non-carriers.  
Arachidonic acid metabolites contribute to the regulation of vascular tone and therefore 
tissue blood flow (Imig 2000; Gauthier et al., 2004). The vascular endothelium metabolizes 
arachidonic acid by cytochrome P450 epoxygenases to epoxyeicosatrienoic acids or EETs. In 
the vasculature, EETs are key components of cellular signaling cascades that cumulate in the 
activation of smooth muscle potassium channels to induce membrane hyperpolarization 
and vascular relaxation. Smoking habit might induce the hypercoagulable state by 
increasing platelet aggregability and had been recognized as a potent risk factor for 
premature MI (Teng et al., 1994).  
In current gene-phenotype functional study, we successfully demonstrated that this genetic 
variant could influence the active EETs metabolites concentrations among premature MI 
subjects. Patients carrying T allele at promoter region of CYP2J2 gene thus had lower 
median value of 14,15 EETs concentrations, which might protect their coronary 
vasculatures. In addition, smoking could alter the metabolites of arachidonic acid (Ye et al., 
2004). This effect was observed, in our study, more significantly among CYP2J2 G-50T 
polymorphism carriers whom probably were more prone to the oxidative stress damage due 
to their impaired EETs functions. These combination effects might explain the possible 
mechanism for the synergistic effect of smoking behavior and the functional change of EETs 
activities by polymorphism with different genotypes in its promoter gene. 
4.3 Modification effects of smoking cessation and its association with gene variation 
on prognosis 
Smokers have twice the risk of dying of coronary heart disease or stroke, and the risk 
diminishes by half in the first year after cessation. After 5–15 years of smoking cessation, the 
risk of both stroke and heart disease drops to the level of never-smokers. Previous studies 
usually used the history of smoking rather than current status of smoking for analysis (Li et al., 
2002; Sacks et al., 1996). Our study analyzed the influence of smoking cessation on the 
prognosis following MI and found that those who kept on smoking could have a higher risk 
for subsequent coronary events when compared with those who stopped smoking. Moreover, 
among patients carrying higher risk genetic background, which indicated the T allele gene, the 
benefit was even greater from smoking cessation. It seems that a gene–environment 
modification relationship exists between smoking behavior and the CYP2J2 gene variation.  
In fact, the smoking behavior alone is a potent risk factor for MI at a young age (Teng et al., 
1994; Liu et al., 2003). Smoking, in supporting of our current in vitro and in vivo findings, can 
also reduce the activities of DHET and may explain partially the possible mechanism for the 
smoking behavior alone or its interaction with gene variation to change the CYP2J2 gene 
activity. Our findings also suggest that successful smoking cessation is very important and 
can improve the cardiovascular outcome, especially among those patients carrying high-risk 
genes. 
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5. Conclusion 
There was a significant association between the polymorphism of G-50T genotype in the 
promoter region of CYP2J2 gene and premature MI in Taiwan. Both the CYP2J2 G-50T 
genotype and smoking were independent risk factors for young MI population. A synergistic 
effect between these two risk factors for the premature onset of MI had been shown in 
subgroup analyses. In addition, there was a significant association between the CYP2J2 G-50T 
genotype and the prognosis after index premature MI. Successful smoking cessation after MI 
also could reduce the incidence of recurrent coronary events, especially among high-risk 
genetic background populations. Such findings lend credence to the concept that genetics and 
environment should not be viewed as independent risk factors for a particular disease; rather, 
environment and genetics interact with each to determine overall health.  
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